EU OK's Lilly's Novartis animal health buy; Mylan ups 2014 guidance range;

@FiercePharma: Did you miss our latest special report yesterday? Not to worry: Top 10 pharma companies by employees - 2014. Report | Follow @FiercePharma

@CarlyHFierce: Salix drops Cosmo buy, opting to talk takeover with Actavis. More | Follow @CarlyHFierce

> The EU has approved Eli Lilly's ($LLY) acquisition of Novartis' ($NVS) animal health unit. More

> Mylan ($MYL) has increased its third quarter and full year 2014 adjusted diluted EPS guidance range. Release

> A federal judge in Newark, NJ, has remanded 57 cases concerning Sanofi ($SNY) and Bristol-Myers Squibb's ($BMY) Plavix to state court after rejecting claims that the plaintiffs fraudulently joined distributor McKesson ($MCK) to defeat diversity jurisdiction. More

> A California federal judge has remanded a wrongful death suit against AbbVie ($ABBV) over its AndroGel testosterone drug to state court, rejecting the company's bid to stay the suit while waiting for it to be transferred to the multidistrict litigation in Illinois over alleged injuries from testosterone treatments. More (sub. req.)

> Antibiotics use in livestock is rising, the FDA has found. More (sub. req.)

> LEO Pharma's Taclonex Topical Suspension has won an indication to treat scalp plaque psoriasis in pediatric patients ages 12-17. Release

Medical Device News

@FierceMedDev: Have you checked out our 15 most promising #medtech companies yet? Report | Follow @FierceMedDev

@VarunSaxena2: Alnylam says it wants to enter larger disease areas using partnership-driven approach. News | Follow @VarunSaxena2

@EmilyWFierce: FDA cracking down on companies marketing essential oils as treatments or cures for Ebola. More from the WSJ | Follow @EmilyWFierce

> Hopkins physician creates 3-D printed hands for pediatric patients. More

> EU regulators to conduct antitrust probe of $13.4B Zimmer/Biomet deal. Story

> Glooko enables wireless smartphone access for existing blood glucose monitors. News

Biotech News

@FierceBiotech: IPO hopeful rEVO puts off its plans for a $75M debut. Item | Follow @FierceBiotech

@JohnCFierce: Interesting to see which #biotech #IPOs do well and which flop. Congrats to $DERM. | Follow @JohnCFierce

@DamianFierce: ICYMI: $LLY's bailing on tabalumab­ in lupus after two Phase III misses. Release | Follow @DamianFierce

@EmilyMFierce: Did you miss our list of notable academic-pharma alliances of 2014? Check it out here. | Follow @EmilyMFierce

> Report: Arbor Pharma goes on the block for $1B-plus. Story

> EMA adopts open trial data policy to begin Jan. 1. Article

> Dermira pulls off a $125M IPO as biotechs wax and wane on Wall Street. News

And Finally... Overprescribing of painkillers is fueling nearly 17,000 annual deaths from overdoses in the United States as well as a rise in heroin use, a new CDC study says. Report

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.